- Conditions
- Catheter-related Infections
- Interventions
- Mino-Lok, Antibiotic lock
- Drug
- Lead sponsor
- Leonard-Meron Biosciences, Inc.
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 144 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 19
- States / cities
- Washington D.C., District of Columbia • Gainesville, Florida • Hines, Illinois + 16 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1657–1680
of 11,344
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Cytomegalovirus Infection
- Interventions
- Placebo, Valganciclovir
- Other · Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- Up to 30 Days
- Enrollment
- 109 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2013
- U.S. locations
- 41
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Little Rock, Arkansas + 34 more
- Conditions
- Advanced Malignant Solid Neoplasm, Recurrent Ependymoma, Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Recurrent Glioma, Recurrent Hepatoblastoma, Recurrent Kidney Wilms Tumor, Recurrent Langerhans Cell Histiocytosis, Recurrent Malignant Germ Cell Tumor, Recurrent Malignant Glioma, Recurrent Malignant Solid Neoplasm, Recurrent Medulloblastoma, Recurrent Neuroblastoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Osteosarcoma, Recurrent Rhabdoid Tumor, Recurrent Rhabdomyosarcoma, Recurrent Soft Tissue Sarcoma, Refractory Ependymoma, Refractory Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Refractory Glioma, Refractory Hepatoblastoma, Refractory Langerhans Cell Histiocytosis, Refractory Malignant Germ Cell Tumor, Refractory Malignant Glioma, Refractory Malignant Solid Neoplasm, Refractory Medulloblastoma, Refractory Neuroblastoma, Refractory Non-Hodgkin Lymphoma, Refractory Osteosarcoma, Refractory Primary Central Nervous System Neoplasm, Refractory Rhabdoid Tumor, Refractory Rhabdomyosarcoma, Refractory Soft Tissue Sarcoma
- Interventions
- Biospecimen Collection, Bone Marrow Aspiration and Biopsy, Bone Scan, Computed Tomography, Larotrectinib Sulfate, Magnetic Resonance Imaging, Radionuclide Imaging, X-Ray Imaging
- Procedure · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 12 Months to 21 Years
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2027
- U.S. locations
- 122
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Mesa, Arizona + 95 more
- Conditions
- Steroid Refractory Acute Graft Versus Host Disease
- Interventions
- Methoxsalen, Extracorporeal Photopheresis (ECP)
- Drug · Procedure
- Lead sponsor
- Therakos, Inc., a Mallinckrodt Company
- Industry
- Eligibility
- 1 Year to 21 Years
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 17
- States / cities
- Phoenix, Arizona • Los Angeles, California • New Haven, Connecticut + 13 more
- Conditions
- Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma, Metastatic Digestive System Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Malignant Neoplasm in the Brain, Metastatic Malignant Solid Neoplasm, Metastatic Melanoma, Metastatic Renal Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8
- Interventions
- Computed Tomography, Fractionated Stereotactic Radiation Therapy, Magnetic Resonance Imaging, Stereotactic Radiosurgery
- Procedure · Radiation
- Lead sponsor
- NRG Oncology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 274 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2033
- U.S. locations
- 262
- States / cities
- Tucson, Arizona • Fort Smith, Arkansas • Little Rock, Arkansas + 189 more
- Conditions
- Acute Myeloid Leukemia
- Interventions
- Pracinostat, Placebos, Azacitidine
- Drug
- Lead sponsor
- Helsinn Healthcare SA
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 406 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 30
- States / cities
- Phoenix, Arizona • Tempe, Arizona • Tucson, Arizona + 25 more
- Conditions
- Stem Cell Transplant Complications, Myeloma, Lymphoma, Allogeneic and Autologous Stem Cell Transplant
- Interventions
- physical therapy consult, Cognitive Assessment, Cancer Aging Research Group (CARG) assessment, Medication Review, Nutrition assessment, Laboratory studies, Patient satisfaction questionnaire, Physician Questionnaire, Patient follow-up questionnaire
- Other
- Lead sponsor
- Case Comprehensive Cancer Center
- Other
- Eligibility
- Not listed
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Lymphoma
- Interventions
- bexarotene, methoxsalen, UV light therapy
- Drug · Procedure
- Lead sponsor
- Millennix
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2001
- U.S. locations
- 19
- States / cities
- Birmingham, Alabama • Little Rock, Arkansas • Stanford, California + 14 more
- Conditions
- Idiopathic Pulmonary Fibrosis
- Interventions
- Placebo, BI 3810477
- Other · Biological
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 13
- States / cities
- Tucson, Arizona • Newport Beach, California • Palo Alto, California + 10 more
- Conditions
- Frontotemporal Lobar Degeneration (FTLD), Progressive Supranuclear Palsy (PSP), Corticobasal Degeneration (CBD), Behavioral Variant Frontotemporal Dementia (bvFTD), Semantic Variant Primary Progressive Aphasia (svPPA), Nonfluent Variant Primary Progressive Aphasia (nfvPPA), FTD With Amyotrophic Lateral Sclerosis (FTD/ALS), Amyotrophic Lateral Sclerosis, Oligosymptomatic PSP (oPSP), C9orf72, GRN Related Frontotemporal Dementia, MAPT Gene Mutation, TBK1 Gene Mutation, Oligosymptomatic Progressive Supranuclear Palsy
- Interventions
- Not listed
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 2,100 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2030
- U.S. locations
- 24
- States / cities
- Birmingham, Alabama • Los Angeles, California • San Diego, California + 20 more
- Conditions
- Leukemia
- Interventions
- Quizartinib, Placebo, Chemotherapy
- Drug
- Lead sponsor
- Daiichi Sankyo
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 700 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2030
- U.S. locations
- 52
- States / cities
- Goodyear, Arizona • Phoenix, Arizona • Tucson, Arizona + 43 more
- Conditions
- Apnea of Prematurity, Intermittent Hypoxemia, Bradycardia
- Interventions
- Womb sound recordings
- Other
- Lead sponsor
- Case Western Reserve University
- Other
- Eligibility
- 1 Week to 5 Weeks
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Idiopathic Gastroparesis
- Interventions
- CIN-102 Dose 15mg, Placebo, CIN-102 Dose 10mg
- Drug
- Lead sponsor
- CinDome Pharma, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 416 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 85
- States / cities
- Birmingham, Alabama • Foley, Alabama • Saraland, Alabama + 78 more
- Conditions
- Acute Coronary Syndrome
- Interventions
- Triage CardioProfilER (Troponin I, Myoglobin, CK-MB, BNP)
- Device
- Lead sponsor
- Abbott RDx Cardiometabolic
- Other
- Eligibility
- 21 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2003
- U.S. locations
- 6
- States / cities
- Sacramento, California • Detroit, Michigan • Charlotte, North Carolina + 3 more
- Conditions
- Kidney Diseases, Diabetic Nephropathies, Glomerulosclerosis, Focal Segmental, Nephrosis, Lipoid, Urologic Diseases, Diabetes Complications, Diabetes Mellitus, Endocrine System Diseases, Glomerulonephritis, Nephritis, Nephrosis
- Interventions
- GFB-887, Placebo
- Drug
- Lead sponsor
- Goldfinch Bio, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 96 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 74
- States / cities
- Birmingham, Alabama • Mesa, Arizona • Scottsdale, Arizona + 66 more
- Conditions
- Relapsed or Refractory Multiple Myeloma
- Interventions
- mezigdomide, Pomalidomide, Bortezomib, Dexamethasone
- Drug
- Lead sponsor
- Celgene
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 810 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2033
- U.S. locations
- 56
- States / cities
- Los Alamitos, California • San Diego, California • West Hollywood, California + 50 more
- Conditions
- Infant, Newborn, Hypertension, Pulmonary, Persistent Fetal Circulation Syndrome, Pneumonia, Aspiration, Respiratory Distress Syndrome, Newborn, Respiratory Insufficiency
- Interventions
- Inhaled nitric oxide, Placebo
- Drug
- Lead sponsor
- NICHD Neonatal Research Network
- Network
- Eligibility
- Up to 14 Days
- Enrollment
- 235 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1995 – 1998
- U.S. locations
- 11
- States / cities
- Palo Alto, California • New Haven, Connecticut • Washington D.C., District of Columbia + 8 more
- Conditions
- HIV Infections
- Interventions
- Atazanavir, Nelfinavir mesylate, Stavudine, Didanosine
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2001
- U.S. locations
- 16
- States / cities
- Birmingham, Alabama • San Diego, California • San Francisco, California + 10 more
- Conditions
- Alzheimer Disease
- Interventions
- Gantenerumab, Placebo
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 50 Years to 90 Years
- Enrollment
- 975 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 47
- States / cities
- Phoenix, Arizona • Sun City, Arizona • Fayetteville, Arkansas + 39 more
- Conditions
- Metastatic Pancreatic Ductal Adenocarcinoma, PDAC
- Interventions
- Telisotuzumab adizutecan, Fluorouracil, Folinic acid/ Leucovorina, Oxaliplatin, Irinotecan
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 900 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 9
- States / cities
- New Haven, Connecticut • Chicago, Illinois • Zion, Illinois + 6 more
- Conditions
- Meningococcal Meningitis, Measles, Mumps, Rubella, Varicella
- Interventions
- Meningococcal Polysaccharide Diphtheria Conjugate Vaccine, Measles, Mumps, Rubella and Varicella
- Biological
- Lead sponsor
- Sanofi Pasteur, a Sanofi Company
- Industry
- Eligibility
- 9 Months to 12 Months
- Enrollment
- 1,664 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2006 – 2009
- U.S. locations
- 87
- States / cities
- Tuscaloosa, Alabama • Tucson, Arizona • Jonesboro, Arkansas + 74 more
- Conditions
- Crohn Disease
- Interventions
- high ligation of ileocolic artery, mesenteric sparing
- Procedure
- Lead sponsor
- The Cleveland Clinic
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 4
- States / cities
- Los Angeles, California • Stanford, California • Weston, Florida + 1 more
- Conditions
- Cushing Syndrome
- Interventions
- ATR-101, Placebo
- Drug
- Lead sponsor
- Millendo Therapeutics US, Inc.
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 3
- States / cities
- Boston, Massachusetts • Cleveland, Ohio • Milwaukee, Wisconsin
- Conditions
- Sarcoma
- Interventions
- dactinomycin, cyclophosphamide, doxorubicin hydrochloride, etoposide, ifosfamide, irinotecan hydrochloride, vincristine sulfate, conventional surgery, radiation therapy, filgrastim
- Biological · Drug · Procedure + 1 more
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- Up to 49 Years
- Enrollment
- 109 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2019
- U.S. locations
- 143
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 118 more